NCT06440187View on ClinicalTrials.gov

Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Recurrent or Metastatic Nasopharyngeal Carcinom
Interventions
DRUG

Gemcitabine+ nivolumab

Gemcitabine+ nivolumab q 2wks

Trial Locations (1)

110-744

Department of Internal Medicine, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT06440187 - Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 | Biotech Hunter | Biotech Hunter